Immunology Program

The Michael Glickman Lab

Michael S. Glickman, MD

Professor

We are broadly interested in the biology of mycobacteria, which include the major human pathogen M. tuberculosis, the nonpathogenic model organism M. smegmatis, and the cancer biotherapeutic agent BCG.

View Lab Overview

Research Projects

Featured News

At Work: Infectious Diseases Specialist Michael Glickman

Physician-scientist Michael Glickman cares for cancer patients who have infections. In his laboratory, he aims to understand how infections develop.

MSK Scientists Solve One of TB’s Deadliest Tricks

Scientists at Memorial Sloan Kettering have pieced together the biochemical mechanism by which the tuberculosis bacterium sneaks past our immune defenses.

MSK physician-scientists Michael Glickman and Gil Redelman-Sidi

The ABCs of BCG: Oldest Approved Immunotherapy Gets New Explanation

BCG has been used to treat bladder cancer for more than 30 years. Scientists are still learning how it works.

Publications Highlights

Distinctive roles of translesion polymerases DinB1 and DnaE2 in diversification of the mycobacterial genome through substitution and frameshift mutagenesis, P Dupuy, S Ghosh, O Adefisayo, J Buglino, S Shuman, MS Glickman, Nature Communications 13 (1), 4493

Roles for mycobacterial DinB2 in frameshift and substitution mutagenesis, P Dupuy, S Ghosh, A Fay, O Adefisayo, R Gupta, S Shuman, …Elife 12, e83094

View All Publications

People

Michael S. Glickman, MD

Professor

Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including the use of mycobacteria as bacterial cancer therapies.
MD, Columbia University College of Physicians and Surgeons

[email protected]: Email Address
646-888-2368: Office Phone
View physician profile: Physician profile

Members

Michael Glickman, MD — Michael Glickman
Member

John Buglino, PhD — John Buglino
Senior Research Scientist

Allison Fay, PhD — Allison Fay
Senior Research Scientist

Gil Redelman-Sidi, MD — Gil Redelman-Sidi
Assistant Attending Physician

Jamie Bean
Assistant Lab Member, EIO Cell Bank director

Veronica Shields
Administrative Assistant

Lab Alumni

Richa Gupta, PhD — Richa Gupta
Research Fellow

Brook Heaton

Research Scholar

Nathaniel Lazar

Graduate Student

Han-guang Yan
Senior Research Technician

Oyindamola Adefisayo, BA — Oyindamola Adefisayo
Graduate Student

Olivier Levy, PhD — Olivier Levy
Postdoctoral Fellow

Bernadette Lynn

Technician

Dave van Ditmarsch, PhD — Dave van Ditmarsch
Research Associate

Charles Vorkas, MD — Charles Vorkas
ID fellow

Matthew Wipperman, Ph.D., M.Sc — Matthew Wipperman
Postdoctoral Fellow

Nicolas Stephanou

Daniel Barkan

Fellow

Vivek Rao

Hideki Makinoshima

Feng Gao

Pratima Kunwar

Paola Bongiorno

Jideofer Aniukwu

Linda Chu

Christina Stallings

Hock-Yong E

Joseph Sklar, PhD — Joseph Sklar
Research Fellow

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

[email protected]

Lab Head Email
646-888-2368

Office Phone
646-422-0502

Office Fax
646-888-2360

Lab Phone
646-422-0502

Lab Fax
Michael Glickman's Twitter

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael S. Glickman discloses the following relationships and financial interests:

Fimbrion Therapeutics, Inc.
Professional Services and Activities (Uncompensated)

Vedanta
Equity; Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures